Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) traded down 2% on Thursday . The stock traded as low as $19.62 and last traded at $19.93, with a volume of 875,075 shares trading hands. The stock had previously closed at $20.33.

Several equities analysts have commented on the stock. Jefferies Group reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Monday, April 18th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday. Leerink Swann set a $33.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday. Cowen and Company reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Finally, Noble Financial reiterated a “buy” rating and issued a $51.00 price target on shares of Heron Therapeutics in a research note on Wednesday, April 20th. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $48.00.

The company’s 50 day moving average price is $17.83 and its 200-day moving average price is $18.84.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts anticipate that Heron Therapeutics Inc. will post ($3.89) EPS for the current fiscal year.

In related news, insider Robert Rosen sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the sale, the insider now directly owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Other large investors have recently bought and sold shares of the company. Swiss National Bank purchased a new stake in Heron Therapeutics during the fourth quarter valued at about $1,100,000. California State Teachers Retirement System raised its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock valued at $1,447,000 after buying an additional 1,000 shares in the last quarter. California Public Employees Retirement System raised its stake in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock valued at $2,419,000 after buying an additional 81,200 shares in the last quarter. Finally, Bank of Montreal Can purchased a new stake in Heron Therapeutics during the fourth quarter valued at about $3,010,000.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.